RANI
Rani Therapeutics Holdings Inc - Ordinary Shares Class A

2,273
Mkt Cap
$187.13M
Volume
1.4M
52W High
$3.87
52W Low
$0.387
PE Ratio
-1.95
RANI Fundamentals
Price
$1.58
Prev Close
$1.54
Open
$1.47
50D MA
$1.25
Beta
1.21
Avg. Volume
43.07M
EPS (Annual)
-$1.05
P/B
-9.39
Rev/Employee
$9,790.48
Loading...
Loading...
News
all
press releases
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Investors Purchase High Volume of Put Options on Rani Therapeutics (NASDAQ:RANI)
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Stock investors acquired 12,455 put options on the stock. This...
MarketBeat·7d ago
News Placeholder
Rani Therapeutics (NASDAQ:RANI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
Rani Therapeutics (NASDAQ:RANI - Get Free Report) released its earnings results on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat·13d ago
News Placeholder
Why Is Rani Therapeutics’ Stock Skyrocketing Pre-Market Today?
The total potential payments from the collaboration could reach $1.085 billion if all options are exercised.
Stocktwits·1mo ago
News Placeholder
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week
These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.
Stocktwits·9mo ago
News Placeholder
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Buy" by Analysts
Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been given an average recommendation of "Buy" by the six research firms that are covering the company, MarketBeat...
Zolmax·2y ago
News Placeholder
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call Transcript
Related Stocks: NAS:RANI...
GuruFocus·2y ago
News Placeholder
Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript
Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript...
SeekingAlpha·2y ago
News Placeholder
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1...
Globe Newswire·2y ago
News Placeholder
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ( Rani Therapeutics or Rani ) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Globe Newswire·2y ago

Latest RANI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.